---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Evaluation of an Internet-Based Disease Trajectory Decision Tool for Prostate Cancer Screening.
To: mesothelioma77@gmail.com
[1]Value Health. 2008 Jul 11;
Bhatnagar V, Frosch DL, Tally SR, Hamori CJ, Lenert L, Kaplan RM
Objective: To evaluate the application of a chronic disease model (CDM) for prostate cancer to visual analog scale (VAS) and time trade-off (TTO) decision tools. Methods: A total of 138 men (mean age 58 years) viewed a CDM module for prostate cancer with and without prostate specific antigen (PSA) screening. Participants rated their hypothetical quality of life with potential prostate cancer treatment complications using a CDM-based VAS decision tool. They were then asked to estimate how many years they would be willing to trade to be free of treatment complications using a CDM-based TTO decision tool. The consistency between VAS and TTO scores and the relationship between scores and preferences for PSA screening test and hypothetical treatment choice for prostate cancer were then evaluated. Results: There was a significant relationship between the VAS and TTO ratings (regression P
___
Source: http://www.hubmed.org/display.cgi?uids=18637139
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Evaluation of an Internet-Based Disease Trajectory Decision Tool for Prostate Cancer Screening.
To: mesothelioma77@gmail.com
[1]Value Health. 2008 Jul 11;
Bhatnagar V, Frosch DL, Tally SR, Hamori CJ, Lenert L, Kaplan RM
Objective: To evaluate the application of a chronic disease model (CDM) for prostate cancer to visual analog scale (VAS) and time trade-off (TTO) decision tools. Methods: A total of 138 men (mean age 58 years) viewed a CDM module for prostate cancer with and without prostate specific antigen (PSA) screening. Participants rated their hypothetical quality of life with potential prostate cancer treatment complications using a CDM-based VAS decision tool. They were then asked to estimate how many years they would be willing to trade to be free of treatment complications using a CDM-based TTO decision tool. The consistency between VAS and TTO scores and the relationship between scores and preferences for PSA screening test and hypothetical treatment choice for prostate cancer were then evaluated. Results: There was a significant relationship between the VAS and TTO ratings (regression P
___
Source: http://www.hubmed.org/display.cgi?uids=18637139
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc